ImmunoGen, Inc. (0A8K.L)

ImmunoGen, Inc. (0A8K.L) — VMCI valuation read

0A8K.L screens at VMCI 35/100, a 15-point gap below the Healthcare sector median (50). For a mid-cap ImmunoGen, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

0A8K.L has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 0A8K.L trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.0x leaves covenant headroom, which sets the rate-cycle exposure for ImmunoGen, Inc..

0A8K.L fell 3.2% over the trailing 7 days, with a +5.1% read on a 30-day basis.